TriangleDatopotamab Deruxtecan (NCT06176261)
Datopotamab Deruxtecan trial for Breast Cancer (NCT06176261). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with HER2-negative breast cancer and new or progressing brain metastases, or leptomeningeal spread. The ER-positive brain-metastasis group requires endocrine-treatment progression; the other groups do not require prior treatment.
The idea: intravenous datopotamab deruxtecan binds TROP2 and delivers a drug that damages DNA. All groups receive treatment every three weeks. Spinal-fluid sampling is optional in brain-metastasis groups but included in the leptomeningeal group. Researchers measure brain response and safety.
This phase 2 study plans 58 patients. Nancy Lin leads at Dana-Farber in Boston; three US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.